Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2030

Conditions
Merkel Cell CarcinomaMerkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage IIMerkel Cell Carcinoma, Stage IIINeuroendocrine TumorsCarcinoma Neuroendocrine Skin
Interventions
DRUG

Avelumab

Avelumab IV infusion

DRUG

Placebo

Placebo IV infusion

Trial Locations (20)

2050

Chris O'Brien Lifehouse, Sydney

2065

Melanoma Institute Australia, Sydney

Royal North Shore Hospital, Sydney

2145

Westmead Hospital, Sydney

2298

Calvary Mater Hospital, Sydney

2444

Port Macquarie Base Hospital, Port Macquarie

2500

Cancer Care Wollongong, Wollongong

3000

Alfred Hospital, Melbourne

Peter MacCallum Cancer Centre, Melbourne

4029

Royal Brisbane and Woman's Hospital, Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

4215

Tasman Health Care, Southport

4655

Cancer Care Service, Hervey Bay Hospital, Hervey Bay

4670

Cancer Care Service, Bundaberg Base Hospital, Bundaberg

4740

Mackay Hospital and Health Service, Mackay

4870

Cairns Hospital, Cairns

5000

Royal Adelaide Hospital, Adelaide

7000

Icon Cancer Centre Hobart, Hobart

Unknown

Townsville Hospital, Townsville

Auckland City Hospital, Auckland

All Listed Sponsors
lead

Melanoma and Skin Cancer Trials Limited

OTHER